{Reference Type}: Case Reports
{Title}: Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
{Author}: Li Y;Zhang J;Cai Z;Gao X;Zhang L;Lu Z;Wang X;Yu P;Li J;Fang F;
{Journal}: Front Oncol
{Volume}: 13
{Issue}: 0
{Year}: 2023
{Factor}: 5.738
{DOI}: 10.3389/fonc.2023.1286392
{Abstract}: <B>UNASSIGNED: </B>Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advanced breast cancer (ABC) patients, long-term treatment often leads to drug resistance, complicating further treatment options. RC48, an antibody-drug conjugate (ADC), combines the benefits of antibody targeting with the cytotoxic effects of a small molecule drug.<BR><B>UNASSIGNED: </B>We present a case involving a female patient with HER2-positive ABC who developed drug resistance and disease progression following multi-line anti-HER2 targeted therapy. In this instance, RC48 exhibited anti-tumor activity in an ABC patient resistant to HER2-targeted therapy. After eight treatment cycles with 120 mg of RC48, the tumor size decreased and stabilized.<BR><B>UNASSIGNED: </B>This case report underscores the potential clinical value of RC48 as a promising treatment alternative for patients resistant to HER2 targeted therapies.